21 results about "Arginase" patented technology

The present invention relates to new polypeptides derived from arginase 2. The present invention also relates to uses of said polypeptides and compositions comprising said polypeptides.

The present disclosure relates to a compound represented by Chemical Formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same can be used favorably for preventing or treating cancer or tumors.

The present invention relates to novel polypeptides, which are derived from Arginase2. The invention also concerns uses of the polypeptides and compositions comprising the polypeptides.

The present invention relates to a compound represented by chemical formula 1, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof can be effectively used for the prevention or treatment of cancer or tumors. [Chemical formula 1] In chemical formula 1, R is as defined in the specification.

The present invention describes methods for producing recombinant arginase enzymes, such as pegylated cobalt substituted recombinant human arginase 1. Also described are pharmaceutical compositions comprising such recombinant arginases, as well as methods of treatment and uses of such recombinant arginases.

The present invention describes methods for producing recombinant arginase enzymes, such as pegylated cobalt substituted recombinant human arginase 1. Also described are pharmaceutical compositions comprising such recombinant arginases, as well as methods of treatment and uses of such recombinant arginases.

Methods for producing recombinant arginase, such as PEGylated and cobalt-substituted recombinant human arginase 1, are described. Pharmaceutical compositions containing this recombinant arginase, as well as methods of processing and uses thereof, are also described.

The application discloses arginase 2 inhibiting peptides and application thereof in wound healing. The arginase 2 inhibiting peptide has an amino acid sequence as shown in SEQ ID No. 1 or a mutant sequence thereof. It is found through research of the application at a cell level and in a mouse skin wound model that MUT4-short peptide and MUT5-short peptide can effectively improve the viability and migration ability of keratinocytes under high-sugar conditions in vitro and in a metabolic abnormality model in vivo, reduce the intracellular reactive oxygen level, and promote the repair process of skin wounds, wherein the MUT4-short peptide shows more significant in promoting the recovery of cell functions and accelerating wound healing, and has a good application prospect in promoting skin wound healing, especially in the treatment of difficult-to-heal wounds related to metabolic diseases such as diabetes.

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.

The present invention relates to a compound represented by chemical formula 1 below, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same may be effectively used for prevention or treatment of cancer or tumors. In chemical formula 1, R is as defined in the specification.

The invention discloses a micro-ecological fermented feed suitable for piglets and a preparation method of the micro-ecological fermented feed, and belongs to the technical field of functional feeds. The preparation method comprises the following steps: 1) preparing functional hydrolysate rich in arginine and branched chain amino acid from plant raw materials through composite enzymolysis; (2) inoculating a functional bacterial agent consisting of lactobacillus plantarum with high arginase activity, nitrate reductase positive bacillus subtilis and clostridium butyricum; (3) accurately controlling the fermentation process by taking the molar ratio of arginine to citrulline being 0.8-1.5 as a fermentation end point, directionally enriching nitric oxide precursors such as citrulline in the feed, and constructing an endogenous NO slow-release system; the product can safely and efficiently activate NO metabolism of intestinal tracts of piglets, synergistically improve intestinal barrier, flora balance, digestive function and whole body immunity, significantly increase daily gain, reduce diarrhea rate, replace zinc oxide and antibiotics, and realize green and healthy breeding.

The present invention relates to a transient intentional ischemia of a part of the liver by occlusion of a selected hepatic vein, subsequently causing reperfusion injury, useful for the treatment of cancer via the endogenous release of liver enzymes, including liver arginase.

The present invention relates to novel polypeptides derived from arginase 1. The invention also relates to polynucleotides encoding the polypeptides. The invention further relates to compositions comprising the polypeptides and polynucleotides. The invention further relates to uses of the polypeptides, polynucleotides, and compositions.

The present invention relates to a compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising same can be advantageously used for the prevention or treatment of cancer or tumors. [Chemical Formula 1] In chemical formula 1, X1 and X2 are as defined in the specification.

Pharmaceutical compositions and medical uses of modified human arginases are described, and in particular, inter alia, a pharmaceutical composition comprising a protein comprising a human Arginase I amino acid sequence and a non-natural metal coenzyme, wherein the non-natural metal coenzyme is cobalt; a pharmaceutical composition comprising a human Arginase I protein having a metal binding site and comprising at least one amino acid substitution in the metal binding site, wherein the protein exhibits an increase in Arginine hydrolysis resulting in a Kcat / Km at least twofold greater than that of a native human Arginase I; a pharmaceutical composition comprising a fusion protein comprising any of said proteins, as well as medical uses related thereto.

This invention belongs to the field of biotechnology, specifically relating to a biomarker for diagnosing immunosuppressive status in chronic tuberculosis and its application. The biomarker is arginase-1. This invention demonstrates that serum Arginase-1 levels are significantly elevated in the progression of chronic tuberculosis, and are significantly positively correlated with the enrichment ratio of myeloid-derived suppressor cells and the expression levels of T cell exhaustion markers. As a key effector molecule of MDSCs, high expression of Arginase-1 reflects abnormal arginine metabolism and T cell exhaustion caused by MDSC amplification, making it an ideal indicator for assessing the immunosuppressive microenvironment in chronic tuberculosis. Using the biomarker of this invention, serum samples can be detected by simple methods such as ELISA, enabling rapid diagnosis, stratification, and dynamic monitoring of the immune status of patients with chronic tuberculosis.

The present invention relates to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising same can be advantageously used for the prevention or treatment of cancer or tumors. [Chemical Formula 1] In chemical formula 1, R is as defined in the specification.

The application belongs to the technical field of biology, and discloses an arginase mutant and application of a genetically engineered bacterium of the arginase mutant. The arginase mutant is obtained by mutating the 133th and 170th amino acids in the amino acid sequence of human arginase I. Compared with human arginase I, the arginase mutant has significantly improved enzyme activity and good stability, and can efficiently catalyze L-arginine to generate L-ornithine. The genetically engineered bacterium of the arginase mutant has low cost and high conversion rate, and lays a foundation for industrial production of L-ornithine.

The present invention relates to a hypotonic fluid, e.g., water for injection, useful for the treatment of cancer via the endogenous release of liver enzymes, including liver arginase, by infusion of the said fluid into the hepatic vein of a liver segment.

The inventive compounds are small molecule therapeutics that are potent inhibitors of arginase 1 and arginase 2 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.